This finding is supported by the predominance of CD8+ T-cells over CD4+ T-cells among T-cells infiltrating acute and chronic MS lesions and by the fact that drugs that specifically block CD4+ T-cells have been shown to be ineffective. The gene discussed is CD8A; the disease is myeloid sarcoma.